<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/779CA70F-9F69-4C4D-B3F7-09DA4FF63A94"><gtr:id>779CA70F-9F69-4C4D-B3F7-09DA4FF63A94</gtr:id><gtr:name>Apitope</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/315A8B8A-B091-44D3-957F-2C7413143DFA"><gtr:id>315A8B8A-B091-44D3-957F-2C7413143DFA</gtr:id><gtr:name>British Thyroid Foundation (BTF)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Human Genetics</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/779CA70F-9F69-4C4D-B3F7-09DA4FF63A94"><gtr:id>779CA70F-9F69-4C4D-B3F7-09DA4FF63A94</gtr:id><gtr:name>Apitope</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/315A8B8A-B091-44D3-957F-2C7413143DFA"><gtr:id>315A8B8A-B091-44D3-957F-2C7413143DFA</gtr:id><gtr:name>British Thyroid Foundation (BTF)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8138EFCC-847B-4467-9A21-D6921B06EF5E"><gtr:id>8138EFCC-847B-4467-9A21-D6921B06EF5E</gtr:id><gtr:firstName>Anthony Peter</gtr:firstName><gtr:surname>Weetman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/22BA277F-C2AE-4174-BF04-7435D17B59C3"><gtr:id>22BA277F-C2AE-4174-BF04-7435D17B59C3</gtr:id><gtr:firstName>Ramzi</gtr:firstName><gtr:surname>Ajjan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C05E7F58-2CD9-4C51-B431-1250C21A1056"><gtr:id>C05E7F58-2CD9-4C51-B431-1250C21A1056</gtr:id><gtr:firstName>Karim</gtr:firstName><gtr:surname>Meeran</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E8B07E77-CDCF-4C54-AFAA-7978C4674F0C"><gtr:id>E8B07E77-CDCF-4C54-AFAA-7978C4674F0C</gtr:id><gtr:firstName>Petros</gtr:firstName><gtr:surname>Perros</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/01C30684-8834-4DA5-AFF2-B39167107BD9"><gtr:id>01C30684-8834-4DA5-AFF2-B39167107BD9</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:surname>Dayan</gtr:surname><gtr:orcidId>0000-0002-6557-3462</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2B4CA7C4-830B-461E-9B78-A7F281E50870"><gtr:id>2B4CA7C4-830B-461E-9B78-A7F281E50870</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Lazarus</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F84B5E54-48CB-41B9-8385-067CE7D225ED"><gtr:id>F84B5E54-48CB-41B9-8385-067CE7D225ED</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FB4F7711-F521-4AB0-BD5F-3C60E1A64ECD"><gtr:id>FB4F7711-F521-4AB0-BD5F-3C60E1A64ECD</gtr:id><gtr:firstName>Ann</gtr:firstName><gtr:surname>Truesdale</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/408FEF37-CABE-493B-B74A-54B6B408B3D0"><gtr:id>408FEF37-CABE-493B-B74A-54B6B408B3D0</gtr:id><gtr:firstName>Diana</gtr:firstName><gtr:otherNames>Ruth</gtr:otherNames><gtr:surname>Elbourne</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0D664919-39C4-4638-AB75-E82A428AB7F8"><gtr:id>0D664919-39C4-4638-AB75-E82A428AB7F8</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Pearce</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A3122EDD-F210-4FDB-9338-2D795F8AD34D"><gtr:id>A3122EDD-F210-4FDB-9338-2D795F8AD34D</gtr:id><gtr:firstName>Amit</gtr:firstName><gtr:surname>Allahabadia</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DB736AFF-072B-4899-B0CD-BCB2B3AA8BBA"><gtr:id>DB736AFF-072B-4899-B0CD-BCB2B3AA8BBA</gtr:id><gtr:firstName>Jayne</gtr:firstName><gtr:surname>Franklyn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FB58ED68-B751-46CC-B05C-DBD9424E5056"><gtr:id>FB58ED68-B751-46CC-B05C-DBD9424E5056</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Vanderpump</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/95B7F8A7-4DDD-4E6F-B9C6-5D5C78D2C25C"><gtr:id>95B7F8A7-4DDD-4E6F-B9C6-5D5C78D2C25C</gtr:id><gtr:firstName>Bijayeswar</gtr:firstName><gtr:surname>Vaidya</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EE928636-6765-4EBA-891C-B1A6E1E28B6A"><gtr:id>EE928636-6765-4EBA-891C-B1A6E1E28B6A</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Toft</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500783"><gtr:id>8D55FF50-F5D5-4BC2-A85B-8FCBBA52150B</gtr:id><gtr:title>United Kingdom Trial of Radioiodine Intervention for Subclinical Hyperthyroidism</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500783</gtr:grantReference><gtr:abstractText>Subclinical hyperthyroidism (SH) is a state of mild thyroid gland overactivity, defined by measurement of thyroid hormones in the blood. It is quite common, affecting about 2% of elderly people. Rather like high blood cholesterol levels, most people have no symptoms of SH, but it is associated with an increased risk of vascular disease. The problem is that we don`t know whether treating SH is worthwhile, in terms of benefit to vascular disease rates and other problems.
We will carry out a trial comparing radioiodine treatment of the thyroid gland overactivity to standard therapy for cardiac risk factors in patients with SH. We will follow people with SH for 5 years after the treatment to find out whether this improves the rate of vascular diseases and other problems. This trial will form the first randomised study of treatment for this condition and will inform healthcare decision making for about 200,000 elderly people each year in the UK.</gtr:abstractText><gtr:technicalSummary>Overt and subclinical thyroid diseases are emerging as major, but largely unrecognised, cardiovascular risk factors. However, there is little evidence-base to support clinical practice in this increasingly important area (1). Subclinical hyperthyroidism affects about 2% of the elderly population, and is associated with increased morbidity and mortality (2,3). We propose a multi-centre, open, randomised trial of 400MBq of radioactive iodine (131-I) for subjects over 65 years of age with sustained subclinical hyperthyroidism. The primary endpoint is a composite of circulatory mortality, non-fatal MI, non-fatal stroke and revascularisation procedure, and this will be ascertained for 5 years. Secondary endpoints are all-cause mortality, atrial fibrillation, progression to overt hyperthyroidism and fracture. This investigation will provide robust data to support evidence-based, effective and efficient clinical practice for this common condition.</gtr:technicalSummary><gtr:fund><gtr:end>2008-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>176765</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>British Thyroid Foundation (BTF)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>British Thyroid Foundation 'Healthcare Consumer input'</gtr:description><gtr:id>110F9AEC-08A5-4A55-88BB-A67E5419E5B8</gtr:id><gtr:impact>Mitchell AL, Hickey B, Hickey JL, Pearce SH. Trends in thyroid hormone prescribing and consumption in the UK. BMC Public Health 2009;9:132. PMID: 19432950</gtr:impact><gtr:outcomeId>31320777EAC-1</gtr:outcomeId><gtr:partnerContribution>My work on the TRISH study cemented an excellent working relationship with this consumer group who subsequently approached me to help with some research into National thyroxine prescribing policies. Together we conducted a national consumer survey which was then published: Mitchell AL, Hickey B, Hickey JL, Pearce SH. Trends in thyroid hormone prescribing and consumption in the UK. BMC Public Health 2009;9:132. PMID: 19432950</gtr:partnerContribution><gtr:piContribution>I designed a research questionnaire, analysed the results and wrote up the paper.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute for Ageing and Health</gtr:department><gtr:description>Newcastle 85+ study</gtr:description><gtr:id>3476AD9E-B64F-490F-91A8-2C411F6AA1B8</gtr:id><gtr:impact>Paper in Mechanisms of Ageing Dev</gtr:impact><gtr:outcomeId>jfLzbEnHr6Z-1</gtr:outcomeId><gtr:partnerContribution>Worked to analyse thyroid function in 85+ patient cohort. Publication has already arisen and at least one more is in the pipeline, pending completion of data analysis.</gtr:partnerContribution><gtr:piContribution>Helped in framing the questions about thyroid function, and in interpreting the data, and writing the paper.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>British Thyroid Foundation (BTF)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Hypothyroidism Patient Project</gtr:description><gtr:id>0ADA7CAC-AFF7-4E21-8BE9-FD899CE7B95B</gtr:id><gtr:impact>Provision of patient information. Accessing primary care to educate GPs.</gtr:impact><gtr:outcomeId>545a210f286819.56492788-1</gtr:outcomeId><gtr:partnerContribution>Provided resource to meet and discuss the research agenda</gtr:partnerContribution><gtr:piContribution>Contributing expertise in study design to allow patients to get information</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Apitope</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>APitope</gtr:description><gtr:id>D485264A-6F54-4C0F-A86A-5B7E863FC184</gtr:id><gtr:impact>A novel immunotherapeutic compound is in development. First in man study has started, led by me.</gtr:impact><gtr:outcomeId>545a20157da323.89455122-1</gtr:outcomeId><gtr:partnerContribution>Provided expertise in therapeutic peptide design and immunological tolerance assays.</gtr:partnerContribution><gtr:piContribution>Provided clinical samples for development and testing of a novel therapeutic in vitro. Provided clinical expertise with trial design. First in man clinical trial now underway with first 2 'global' patients dosed at my centre.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Wrote European Guidelines-subclinical hypothyroidism</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>F0ACEE66-4BE6-4078-B107-67816FE1252A</gtr:id><gtr:impact>Fuller appreciation of the (lack of) need to intervene in patients with mild abnormalities of thyroid functions. Saving of healthcare resource</gtr:impact><gtr:outcomeId>545a23d33aee11.00419606</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Journal of Royal College of Physicians</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8F2426BE-91EF-44A9-8BCF-3BC824C8587F</gtr:id><gtr:outcomeId>84E7CB691A5</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18478874</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Trial was a feasibility study of an established therapy, radioiodine, in subclinical hyperthyroidism, a non-standard indication. Recruitemnt to the study was poor, indicating this was not an acceptable intervention for most people with the condition. In addition, some individuals had side effects from the active treatment. Given the low recruitment rate, a full trial would not have been feasible as the intervention wasn't acceptable.</gtr:description><gtr:id>410A9354-2DEE-49E8-B1A7-BB3C180841E6</gtr:id><gtr:impact>The study has led to a change in opinion about the acceptability of the therapy which has been encapsulated in review articles and lectures.</gtr:impact><gtr:outcomeId>hqAUmyh1Eu7</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>TRISH: Trial of radioiodine in subclinical hyperthyroidism</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C8088A3B-E4FD-48DC-9174-1FDD7F756AC2</gtr:id><gtr:title>Low-dose levothyroxine did not improve symptoms in asymptomatic older people with subclinical hypothyroidism.</gtr:title><gtr:parentPublicationTitle>BMJ evidence-based medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/371a05b43455dc2a6eb5d16f94a8d68a"><gtr:id>371a05b43455dc2a6eb5d16f94a8d68a</gtr:id><gtr:otherNames>Pearce SHS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5aa29019a923a2.36802814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF44F553-8E6A-445F-91EF-2B6B2602D3CD</gtr:id><gtr:title>How should we treat patients with low serum thyrotropin concentrations?</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40d4aefc449834f9c0aba834ea778607"><gtr:id>40d4aefc449834f9c0aba834ea778607</gtr:id><gtr:otherNames>Mitchell AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>B5C9542FAFA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68DCD759-FD66-498B-ADEF-3A83AD320BAA</gtr:id><gtr:title>An elderly woman with weight loss and diarrhoea.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40d4aefc449834f9c0aba834ea778607"><gtr:id>40d4aefc449834f9c0aba834ea778607</gtr:id><gtr:otherNames>Mitchell AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5EE26B6A326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>866F78D2-2CA9-4B16-BE6D-A768905DF14F</gtr:id><gtr:title>Assessment of a large panel of candidate biomarkers of ageing in the Newcastle 85+ study.</gtr:title><gtr:parentPublicationTitle>Mechanisms of ageing and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0ef1666b919a77341794a6e86cbf890"><gtr:id>a0ef1666b919a77341794a6e86cbf890</gtr:id><gtr:otherNames>Martin-Ruiz C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0047-6374</gtr:issn><gtr:outcomeId>svfvNtSkr6g</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E20D7C3E-B8BC-4FAB-817A-AE6E9F14377B</gtr:id><gtr:title>Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality.</gtr:title><gtr:parentPublicationTitle>Archives of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09f6d53f9f43c157eaac4587ab4e689c"><gtr:id>09f6d53f9f43c157eaac4587ab4e689c</gtr:id><gtr:otherNames>Razvi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-9926</gtr:issn><gtr:outcomeId>pm_14005_25_22529180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>877C8DDE-364B-470C-8998-81643EF9BAF5</gtr:id><gtr:title>Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement.</gtr:title><gtr:parentPublicationTitle>Thyroid : official journal of the American Thyroid Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb44723b4b9da181ab2eeaaf7e483c77"><gtr:id>cb44723b4b9da181ab2eeaaf7e483c77</gtr:id><gtr:otherNames>Perros P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1050-7256</gtr:issn><gtr:outcomeId>58c16c471a3382.86080251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>255E4127-9786-414E-B398-6F0D000414F0</gtr:id><gtr:title>Clinical review: The thyroid in mind: cognitive function and low thyrotropin in older people.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035d0e4c4756ccd97aba54ac23cbeebc"><gtr:id>035d0e4c4756ccd97aba54ac23cbeebc</gtr:id><gtr:otherNames>Gan EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_14005_25_22865905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1B5D144-B618-421B-AC56-D220F9C0F37A</gtr:id><gtr:title>Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdc6c457093a1bb8563d4717335a8f5e"><gtr:id>fdc6c457093a1bb8563d4717335a8f5e</gtr:id><gtr:otherNames>Vaidya B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>6F1C92159E9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53C3956F-FA7E-4CCA-BC01-746EACF5441F</gtr:id><gtr:title>Subclinical thyroid disorders: significance and clinical impact.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09f6d53f9f43c157eaac4587ab4e689c"><gtr:id>09f6d53f9f43c157eaac4587ab4e689c</gtr:id><gtr:otherNames>Razvi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>dmkGSC1kTpa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F1335E4-CEEF-4707-ACE8-82A72B5311B7</gtr:id><gtr:title>Thyroxine in acute myocardial infarction (ThyrAMI) - levothyroxine in subclinical hypothyroidism post-acute myocardial infarction: study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce43ff993739d6369f242c4309e0daf4"><gtr:id>ce43ff993739d6369f242c4309e0daf4</gtr:id><gtr:otherNames>Jabbar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56cddf011b57e9.83384485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>049D10D2-0065-4E64-8520-064E6635532D</gtr:id><gtr:title>Serum Thyroid Function, Mortality and Disability in Advanced Old Age: The Newcastle 85+ Study.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f78ce76102cae0546d0d6557520cfc67"><gtr:id>f78ce76102cae0546d0d6557520cfc67</gtr:id><gtr:otherNames>Pearce SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>58c16c46607c89.56309120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>156B30A1-1454-4295-BE0F-C7A097E567BE</gtr:id><gtr:title>2013 ETA Guideline: Management of Subclinical Hypothyroidism.</gtr:title><gtr:parentPublicationTitle>European thyroid journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f78ce76102cae0546d0d6557520cfc67"><gtr:id>f78ce76102cae0546d0d6557520cfc67</gtr:id><gtr:otherNames>Pearce SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2235-0640</gtr:issn><gtr:outcomeId>58c16e7fd28504.79533984</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB2C7019-FCB0-4CD8-B966-2E25406B9BBC</gtr:id><gtr:title>Subclinical thyroid disease: time to enter the age of evidence-based medicine.</gtr:title><gtr:parentPublicationTitle>Thyroid : official journal of the American Thyroid Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18e70d7470490681d3c834eb4758bf98"><gtr:id>18e70d7470490681d3c834eb4758bf98</gtr:id><gtr:otherNames>Goichot B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1050-7256</gtr:issn><gtr:outcomeId>pm_14005_25_22853726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EBADF2C-972C-4E52-A0E8-C8D57184C2D8</gtr:id><gtr:title>Serum 25-hydroxyvitamin D concentration and its determinants in the very old: the Newcastle 85+ Study.</gtr:title><gtr:parentPublicationTitle>Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/246b23a964ea830fd5de837956b3b9c8"><gtr:id>246b23a964ea830fd5de837956b3b9c8</gtr:id><gtr:otherNames>Hill TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0937-941X</gtr:issn><gtr:outcomeId>56cddf00116456.51128695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BAFB566-F604-4A7A-9B48-766BC430F4B4</gtr:id><gtr:title>Subclinical hyperthyroidism: first do no harm.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40d4aefc449834f9c0aba834ea778607"><gtr:id>40d4aefc449834f9c0aba834ea778607</gtr:id><gtr:otherNames>Mitchell AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>58c16c46b2e572.08220189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8CBED98-CCCC-4FD3-949F-019C9781C12B</gtr:id><gtr:title>Study of Optimal Replacement of Thyroxine in the Elderly (SORTED) - results from the feasibility randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Thyroid research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09f6d53f9f43c157eaac4587ab4e689c"><gtr:id>09f6d53f9f43c157eaac4587ab4e689c</gtr:id><gtr:otherNames>Razvi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-6614</gtr:issn><gtr:outcomeId>58c16d90ad3cb0.00108100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AF60070-CBBA-4431-AC0F-4EBBC128C48A</gtr:id><gtr:title>Clinical review: A review of the clinical consequences of variation in thyroid function within the reference range.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8b3f0361c55d144c4f9f907c876c0f9"><gtr:id>a8b3f0361c55d144c4f9f907c876c0f9</gtr:id><gtr:otherNames>Taylor PN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_14005_25_23824418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>342B90F5-B2DF-4452-BDB2-D5D6DC57D77A</gtr:id><gtr:title>Thyroid hormones and cardiovascular disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce43ff993739d6369f242c4309e0daf4"><gtr:id>ce43ff993739d6369f242c4309e0daf4</gtr:id><gtr:otherNames>Jabbar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-5002</gtr:issn><gtr:outcomeId>58c16d905f34e2.87200937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CD86DE9-4EDB-47F7-8A36-C67506B2F678</gtr:id><gtr:title>Diagnosis and management of thyrotoxicosis.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdc6c457093a1bb8563d4717335a8f5e"><gtr:id>fdc6c457093a1bb8563d4717335a8f5e</gtr:id><gtr:otherNames>Vaidya B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>545a0003f15530.82075040</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500783</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>6FFAED28-939F-4795-9FD1-98511549B3B8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>